Santhera and Genzyme sign option and licence agreement
Swiss drug discovery and development company Santhera Pharmaceuticals has granted a non-exclusive licence to its proprietary cellular screening system to Genzyme Corporation for the discovery of novel therapies for a variety of muscle diseases including Duchenne Muscular Dystrophy.
Swiss drug discovery and development company Santhera Pharmaceuticals has granted a non-exclusive licence to its proprietary cellular screening system to Genzyme Corporation for the discovery of novel therapies for a variety of muscle diseases including Duchenne Muscular Dystrophy.
Genzyme also has the option to obtain an exclusive worldwide license to develop and commercialise a subset of Santhera's novel small molecule compounds for the treatment of Duchenne Muscular Dystrophy and related diseases.
Under the terms of the agreement, Santhera will receive a technology license fee. Financial details of the transaction were not disclosed.